The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Everolimus (Afinitor) for Neuroendocrine tumours of Gastrointestinal or Lung origin
(Open for Input on Submission until June 13, 2016)
Bevacizumab (Avastin) for Platinum Resistant Ovarian Cancer
(Notification to Implement Issued as of May 20, 2016)